However, within the context of PSMA PET/CT imaging for prostate cancer, prior studies following the VISION trial primarily focused on the prognostic value of semi-quantitative parameters such as SUVmean [25,26,27]. This evidence concerns the gene FOLH1 and prostate carcinoma.